Δημοσιεύσεις σε περιοδικά με κριτές

1. 2026

   Vitamin D levels and skeletal quality of life in adult Langerhans cell histiocytosisΤελευταίος συγγραφέας

   Gravvanis C, Kouveletsou M, Yavropoulou M, …, Makras P, et al. Endocr Connect. PMID 42696272

2. 2026

   Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study

   Yavropoulou MP, Tournis S, Chondrogianni ME, …, Makras P, et al. Eur J Endocrinol. PMID 42656047

3. 2026

   Response to Letter to the Editor on "Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patients"

   Yavropoulou MP, Koloutsou ME, Delaporta P, …, Makras P, et al. JBMR Plus. PMID 42577805

4. 2026

   Challenges in Sequential Antiresorptive Therapy After Long-Term Denosumab Discontinuation: A Case Report and Narrative Review of the Literature

   Koloutsou ME, Pieper MD, Mateniadou M, …, Makras P, et al. J Clin Med. PMID 42513356

5. 2026

   Alendronate for 6 or 12 months following denosumab discontinuation in women with postmenopausal osteoporosis: A prospective observational studyΠρώτος συγγραφέας

   Makras P, Anastasilakis AD, Palermo A, et al. J Bone Miner Res. PMID 42334992

6. 2026

   Osteoporosis and osteoporosis therapies as determinants of implant fixation failure in arthroplasty and spinal fusion constructs: a position statement from the Fracture Working Group of the Council of Scientific Advisors of the International Osteoporosis Foundation

   Chandran M, Anastasilakis AD, Blank RD, …, Makras P, et al. Osteoporos Int. PMID 42313180

7. 2026

   Artificial intelligence vs human opportunistic detection of vertebral fractures in routine CT scans: results of a pilot studyΠρώτος συγγραφέας

   Makras P, Chatzellis E, Gravvanis C, et al. Hormones (Athens). PMID 42026417

8. 2026

   Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patients

   Yavropoulou MP, Koloutsou ME, Delaporta P, …, Makras P, et al. JBMR Plus. PMID 42004613

9. 2026

   Approach to the patient: management of bone fragility in patients with chronic hypoparathyroidism

   Tournis S, Kassi E, Palermo A, …, Makras P, et al. J Clin Endocrinol Metab. PMID 41968412

10. 2026

    The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group

    Bulaicon OO, van Haalen FM, Clunie GPR, …, Makras P, et al. J Clin Endocrinol Metab. PMID 41955566

11. 2026

    Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic mice

    Rinotas V, Ntouskou ED, Dragolia M, …, Makras P, et al. Front Endocrinol (Lausanne). PMID 41837128

12. 2026

    Glucagon-like peptide-1 receptor agonists in orthopaedics

    Mavrogenis AF, Altsitzioglou P, Pililis S, …, Makras P, et al. SICOT J. PMID 41789832

13. 2026

    Successful management of denosumab discontinuation in a patient with primary pediatric osteoporosis

    Anastasilakis AD, Makras P, Polyzos SA, et al. Bone Rep. PMID 41716650

14. 2026

    Repurposing osteoporosis medications for other diseases: a narrative review by the European Calcified Tissue Society (ECTS)Πρώτος συγγραφέας

    Makras P, Yavropoulou MP, Anastasilakis AD, et al. Bone. PMID 41448559

15. 2026

    Phenotype, treatment, and determinants of prognosis in Erdheim-Chester disease: an international, retrospective, cohort study

    Pegoraro F, Peyronel F, Papo M, …, Makras P, et al. Lancet Haematol. PMID 42880331

16. 2026

    Building bone in the jaw with denosumab in adult Langerhans cell histiocytosisΠρώτος συγγραφέας

    Makras P, Kouveletsou M, Siska I, et al. Osteoporos Int. PMID 42867634

17. 2026

    MEK inhibition achieves robust and durable responses in Erdheim-Chester disease

    Pegoraro F, Triboulet F, Papo M, …, Makras P, et al. Hemasphere. PMID 42840804

18. 2025

    Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trialsΤελευταίος συγγραφέας

    Yavropoulou MP, Anastasilakis DA, Kasdagli MI, …, Makras P, et al. BMJ Oncol. PMID 41323423

19. 2025

    The Effects of Obesity and Weight Loss Interventions on Bone Health: A Narrative Review

    Palermo A, Tsourdi E, Yavropoulou MP, …, Makras P, et al. Curr Diab Rep. PMID 41060517

20. 2025

    Correction: Diagnosis and management of hypoparathyroidism: recommendations of the working group of the bone section of the Hellenic endocrine society

    Kassi E, Adamidou F, Yavropoulou MP, …, Makras P, et al. Hormones (Athens). PMID 40924309

21. 2025

    Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the FutureΤελευταίος συγγραφέας

    Papapoulos SE, Makras P. Pharmaceuticals (Basel). PMID 40732355

22. 2025

    Diagnosis and management of hypoparathyroidism: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society

    Kassi E, Adamidou F, Yavropoulou MP, …, Makras P, et al. Hormones (Athens). PMID 40576884

23. 2025

    Diagnosis and management of primary hyperparathyroidism: recommendations from the Bone Section of the Hellenic Endocrine SocietyΤελευταίος συγγραφέας

    Anastasilakis AD, Yavropoulou MP, Kassi E, …, Makras P, et al. Hormones (Athens). PMID 40459662

24. 2025

    No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trialΠρώτος συγγραφέας

    Makras P, Yavropoulou MP, Anastasilakis AD, et al. Osteoporos Int. PMID 40418338

25. 2025

    Bone microstructure and TBS in diabetes: what have we learned? A narrative review

    Ferrari S, Akesson KE, Al-Daghri N, …, Makras P, et al. Osteoporos Int. PMID 40353870

26. 2025

    Follistatins, activins and inhibins during osteoporosis therapy with denosumab or zoledronate and after their discontinuation

    Anastasilakis AD, Makras P, Polyzos SA, et al. Diabetes Obes Metab. PMID 39844694

27. 2025

    Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic DisorderΠρώτος συγγραφέας

    Makras P, Erickson D, Davidge-Pitts CJ, et al. J Clin Endocrinol Metab. PMID 39699236

28. 2025

    Comparison of next generation sequencing (NGS) - (SNPs) and capillary electrophoresis (CE) - (STRs) in the genetic analysis of human remainsΤελευταίος συγγραφέας

    Kokotas S, Budowle B, Papatheodorou A, …, Makras P, et al. Forensic Sci Int Genet. PMID 39241298

29. 2024

    Primary hyperparathyroidism: from guidelines to outpatient clinic

    Palermo A, Tabacco G, Makras P, et al. Rev Endocr Metab Disord. PMID 39162944

30. 2024

    The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis

    Anastasilakis AD, Polyzos SA, Makras P, et al. J Bone Miner Res. PMID 38976019

31. 2024

    Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?

    Anastasilakis AD, Yavropoulou MP, Palermo A, …, Makras P, et al. Eur J Endocrinol. PMID 38938063

32. 2024

    Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review

    Chandran M, Akesson KE, Javaid MK, …, Makras P, et al. Osteoporos Int. PMID 38587674

33. 2024

    Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatmentΠρώτος συγγραφέας

    Makras P, Yavropoulou MP, Anastasilakis AD, et al. Osteoporos Int. PMID 38147135

34. 2024

    Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trials

    Yavropoulou MP, Kasdagli MI, Makras P, et al. Maturitas. PMID 37976923

35. 2024

    The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injectionΠρώτος συγγραφέας

    Makras P, Yavropoulou MP, Polyzos SA, et al. Osteoporos Int. PMID 37783758

36. 2023

    Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab

    Anastasilakis AD, Makras P, Paccou J, et al. J Clin Med. PMID 37762815

37. 2023

    Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study

    Anastasilakis AD, Polyzos SA, Vorkas PA, …, Makras P, et al. J Clin Med. PMID 37629472

38. 2023

    The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis

    Anastasilakis AD, Makras P, Polyzos SA, et al. Calcif Tissue Int. PMID 37535102

39. 2023

    Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study

    Anastasilakis AD, Polyzos SA, Savvidis M, …, Makras P, et al. Endocrine. PMID 37221430

40. 2023

    Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trialΠρώτος συγγραφέας

    Makras P, Yavropoulou MP, Chatziioannou SN, et al. Am J Hematol. PMID 37073626

41. 2023

    Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in GreeceΤελευταίος συγγραφέας

    Souliotis K, Golna C, Poimenidou C, …, Makras P, et al. Patient Prefer Adherence. PMID 36647442

42. 2023

    Activins, follistatins and inhibins in postmenopausal osteoporosis: A proof of concept, case-control study

    Anastasilakis AD, Polyzos SA, Rodopaios NE, …, Makras P, et al. Metabolism. PMID 36587801

43. 2022

    Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisitedΤελευταίος συγγραφέας

    Yavropoulou MP, Anastasilakis AD, Tzoulis P, …, Makras P, et al. Acta Biomed. PMID 36300213

44. 2022

    To screen or not to screen for osteoporosis amongst post-menopausal women with one prior osteoporotic fracture in GreeceΤελευταίος συγγραφέας

    Souliotis K, Golna C, Golnas P, …, Makras P, et al. Aging Clin Exp Res. PMID 35819748

45. 2022

    Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece

    Yavropoulou MP, Makras P, Athanasakis K, et al. Arch Osteoporos. PMID 35761110

46. 2022

    International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults

    Goyal G, Tazi A, Go RS, …, Makras P, et al. Blood. PMID 35271698

47. 2022

    Adult Langerhans Cell Histiocytosis and the SkeletonΤελευταίος συγγραφέας

    Georgakopoulou D, Anastasilakis AD, Makras P. J Clin Med. PMID 35207181

48. 2022

    The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis

    Anastasilakis AD, Papachatzopoulos S, Makras P, et al. Bone. PMID 35150909

49. 2022

    Prevalence of the BRAF (V600E) mutation in Greek adults with Langerhans cell histiocytosisΤελευταίος συγγραφέας

    Stathi D, Yavropoulou MP, Allen CE, …, Makras P, et al. Pediatr Hematol Oncol. PMID 35139731

50. 2022

    Bone turnover markers in gingival crevicular fluid and blood serum of patients with fixed orthodontic appliances

    Kloukos D, Mavrogonatou E, Kletsas D, …, Makras P, et al. Eur J Orthod. PMID 34878106

51. 2022

    Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis

    Geusens P, Feldman R, Oates M, …, Makras P, et al. Bone. PMID 34547521

52. 2021

    Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patientsΠρώτος συγγραφέας

    Makras P, Petrikkos P, Anastasilakis AD, et al. Bone Rep. PMID 34541262

53. 2021

    Denosumab for the treatment of primary pediatric osteoporosis

    Anastasilakis AD, Makras P, Doulgeraki A, et al. Osteoporos Int. PMID 33987688

54. 2021

    The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its DiscontinuationΠρώτος συγγραφέας

    Makras P, Appelman-Dijkstra NM, Papapoulos SE, et al. J Clin Endocrinol Metab. PMID 33978745

55. 2021

    Ιrisin levels in postmenopausal women with an incident hip fracture

    Anastasilakis AD, Polyzos SA, Kitridis D, …, Makras P, et al. Endocrine. PMID 33977311

56. 2021

    Circulating microRNAs Related to Bone Metabolism in HIV-Associated Bone Loss

    Yavropoulou MP, Kolynou A, Makras P, et al. Biomedicines. PMID 33924204

57. 2021

    Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerationsΤελευταίος συγγραφέας

    Polyzos SA, Anastasilakis AD, Efstathiadou ZA, …, Makras P, et al. Maturitas. PMID 33832643

58. 2021

    Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

    Terpos E, Ntanasis-Stathopoulos I, Katodritou E, …, Makras P, et al. Cancers (Basel). PMID 33809268

59. 2021

    Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusionΤελευταίος συγγραφέας

    Anastasilakis AD, Polyzos SA, Yavropoulou MP, …, Makras P, et al. Endocrine. PMID 33651343

60. 2021

    Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid AdenomasΤελευταίος συγγραφέας

    Yavropoulou MP, Pazaitou-Panayiotou K, Yovos JG, …, Makras P, et al. JBMR Plus. PMID 33615103

61. 2021

    Efficacy of Antiosteoporotic Medications in Patients With Rebound-Associated Fractures After Denosumab Discontinuation

    Anastasilakis AD, Polyzos SA, Makras P, et al. J Clin Densitom. PMID 33541775

62. 2021

    Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review

    Anastasilakis AD, Makras P, Yavropoulou MP, et al. J Clin Med. PMID 33406802

63. 2021

    Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab DiscontinuationΤελευταίος συγγραφέας

    Anastasilakis AD, Polyzos SA, Yavropoulou MP, …, Makras P, et al. Calcif Tissue Int. PMID 33386953

64. 2021

    Questions and facts regarding denosumab discontinuation among postmenopausal womenΠρώτος συγγραφέας

    Makras P, Anastasilakis AD. Expert Opin Drug Saf. PMID 33372551

65. 2021

    Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough

    Anastasilakis AD, Trovas G, Balanika A, …, Makras P, et al. J Clin Densitom. PMID 33218880

66. 2020

    Expression of Circulating MicroRNAs Linked to Bone Metabolism in Chronic Kidney Disease-Mineral and Bone Disorder

    Yavropoulou MP, Vaios V, Makras P, et al. Biomedicines. PMID 33322822

67. 2020

    Fracture risk among treatment-naïve postmenopausal women with osteopenia in Greece: results from the "ACROSS" studyΤελευταίος συγγραφέας

    Anastasilakis AD, Makras P. Arch Osteoporos. PMID 33067646

68. 2020

    The annual incidence of Langerhans cell histiocytosis among adults living in GreeceΠρώτος συγγραφέας

    Makras P, Stathi D, Yavropoulou M, et al. Pediatr Blood Cancer. PMID 32618036

69. 2020

    The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosisΠρώτος συγγραφέας

    Makras P, Papapoulos SE, Polyzos SA, et al. Bone. PMID 32534221

70. 2020

    Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis

    Yavropoulou MP, Anastasilakis AD, Makras P, et al. J Clin Endocrinol Metab. PMID 32521543

71. 2020

    Extra-skeletal effects of bisphosphonates

    Panagiotakou A, Yavropoulou M, Nasiri-Ansari N, …, Makras P, et al. Metabolism. PMID 32445641

72. 2020

    Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation

    Anastasilakis AD, Evangelatos G, Makras P, et al. Endocrine. PMID 32441026

73. 2020

    Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation

    Anastasilakis AD, Evangelatos G, Makras P, et al. Bone Rep. PMID 32373677

74. 2020

    Gender Predilection in Sporadic Parathyroid AdenomasΤελευταίος συγγραφέας

    Yavropoulou MP, Anastasilakis AD, Panagiotakou A, …, Makras P, et al. Int J Mol Sci. PMID 32331456

75. 2020

    Management of parathyroid disorders: recommendations of the working group of the Bone Section of the Hellenic Endocrine SocietyΠρώτος συγγραφέας

    Makras P, Yavropoulou MP, Kassi E, et al. Hormones (Athens). PMID 32297171

76. 2020

    Combination and sequential treatment in women with postmenopausal osteoporosisΤελευταίος συγγραφέας

    Anastasilakis AD, Polyzos SA, Yavropoulou MP, …, Makras P. Expert Opin Pharmacother. PMID 31990595

77. 2020

    Experience gained from the implementation of the fracture liaison service in GreeceΠρώτος συγγραφέας

    Makras P, Babis GC, Chronopoulos E, et al. Arch Osteoporos. PMID 31897772

78. 2019

    Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

    Anargyrou K, Fotiou D, Vassilakopoulos TP, …, Makras P, et al. Hemasphere. PMID 31976477

79. 2019

    Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid AdenomaΤελευταίος συγγραφέας

    Florakis D, Karakozis S, Tseleni-Balafouta S, …, Makras P. J Musculoskelet Neuronal Interact. PMID 31475947

80. 2019

    Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass

    Anastasilakis AD, Polyzos SA, Makras P, et al. J Musculoskelet Neuronal Interact. PMID 31475931

81. 2019

    Off-label uses of denosumab in metabolic bone diseases

    Polyzos SA, Makras P, Tournis S, et al. Bone. PMID 31454537

82. 2019

    Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical TrialΤελευταίος συγγραφέας

    Anastasilakis AD, Papapoulos SE, Polyzos SA, …, Makras P, et al. J Bone Miner Res. PMID 31433518

83. 2019

    Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue Society

    Anastasilakis AD, Tsourdi E, Makras P, et al. Bone. PMID 31299385

84. 2019

    Bazedoxifene for the treatment of osteoporosis

    Yavropoulou MP, Makras P, Anastasilakis AD. Expert Opin Pharmacother. PMID 31091133

85. 2019

    The 2018 Guidelines for the diagnosis and treatment of osteoporosis in GreeceΠρώτος συγγραφέας

    Makras P, Anastasilakis AD, Antypas G, et al. Arch Osteoporos. PMID 30877479

86. 2019

    Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?

    Anastasilakis AD, Polyzos SA, Makras P, et al. Metabolism. PMID 30690037

87. 2019

    Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment

    Tsourdi E, Makras P, Rachner TD, et al. Bone. PMID 30292818

88. 2019

    Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview

    Anastasilakis DA, Makras P, Polyzos SA, et al. Hormones (Athens). PMID 30255479

89. 2019

    Hypoparathyroidism: is it that easy to treat?Τελευταίος συγγραφέας

    Triantafyllou E, Yavropoulou MP, Anastasilakis AD, …, Makras P. Hormones (Athens). PMID 29876797

90. 2018

    Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment

    Polyzos SA, Kountouras J, Anastasilakis AD, …, Makras P, et al. Hormones (Athens). PMID 30467685

91. 2018

    Serum 25-hydroxyvitamin D status, quantitative ultrasound parameters, and their determinants in Greek population

    Grigoriou EV, Trovas G, Papaioannou N, …, Makras P, et al. Arch Osteoporos. PMID 30324335

92. 2018

    Bone metabolism in Langerhans cell histiocytosisΤελευταίος συγγραφέας

    Anastasilakis AD, Tsoli M, Kaltsas G, …, Makras P. Endocr Connect. PMID 29967185

93. 2018

    THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosisΤελευταίος συγγραφέας

    Anastasilakis AD, Polyzos SA, Makras P. Eur J Endocrinol. PMID 29691303

94. 2018

    Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?Τελευταίος συγγραφέας

    Anastasilakis AD, Tournis S, Yavropoulou MP, …, Makras P, et al. Calcif Tissue Int. PMID 29492590

95. 2018

    Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis

    Anastasilakis AD, Makras P, Pikilidou M, et al. J Clin Endocrinol Metab. PMID 29309589

96. 2018

    Irisin in metabolic diseases

    Polyzos SA, Anastasilakis AD, Efstathiadou ZA, …, Makras P, et al. Endocrine. PMID 29170905

97. 2018

    Bone disease in primary hyperparathyroidismΠρώτος συγγραφέας

    Makras P, Anastasilakis AD. Metabolism. PMID 29051042

98. 2017

    Periostin and sclerostin levels in juvenile Paget's disease

    Polyzos SA, Makras P, Anastasilakis AD, et al. Clin Cases Miner Bone Metab. PMID 29263750

99. 2017

    Cost-effective osteoporosis treatment thresholds for people living with HIV infection in GreeceΠρώτος συγγραφέας

    Makras P, Boubouchairopoulou N, Katsarolis I, et al. J Musculoskelet Neuronal Interact. PMID 29199188

100. 2017

     Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments

     Dede AD, Makras P, Anastasilakis AD. Expert Opin Investig Drugs. PMID 28836858

101. 2017

     Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium

     Fahrleitner-Pammer A, Papaioannou N, Gielen E, …, Makras P, et al. Arch Osteoporos. PMID 28643265

102. 2017

     Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activityΤελευταίος συγγραφέας

     Anastasilakis AD, Polyzos SA, Tsoli M, …, Makras P, et al. Metabolism. PMID 28521873

103. 2017

     Bisphosphonates or denosumab discontinuation and risk of fracturesΤελευταίος συγγραφέας

     Anastasilakis AD, Yavropoulou MP, Makras P. Maturitas. PMID 28495014

104. 2017

     Denosumab for the treatment of adult multisystem Langerhans cell histiocytosisΠρώτος συγγραφέας

     Makras P, Tsoli M, Anastasilakis AD, et al. Metabolism. PMID 28285639

105. 2017

     Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment

     Anastasilakis AD, Yavropoulou MP, Makras P, et al. Eur J Endocrinol. PMID 28283537

106. 2017

     Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

     Anastasilakis AD, Polyzos SA, Makras P, et al. J Bone Miner Res. PMID 28240371

107. 2017

     Evaluation of the first fracture liaison service in the Greek healthcare settingΠρώτος συγγραφέας

     Makras P, Panagoulia M, Mari A, et al. Arch Osteoporos. PMID 28004297

108. 2017

     Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures

     Yavropoulou MP, Anastasilakis AD, Makras P, et al. Eur J Endocrinol. PMID 27836951

109. 2016

     Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic AcidΠρώτος συγγραφέας

     Makras P, Polyzos SA, Anastasilakis AD. J Clin Endocrinol Metab. PMID 27600205

110. 2016

     Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series

     Chellapandian D, Makras P, Kaltsas G, et al. Mediterr J Hematol Infect Dis. PMID 27413525

111. 2016

     Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physicians' criteria in the choice of treatmentΠρώτος συγγραφέας

     Makras P, Galanos A, Rizou S, et al. Hormones (Athens). PMID 27394706

112. 2016

     Multiple clinical vertebral fractures following denosumab discontinuationΤελευταίος συγγραφέας

     Anastasilakis AD, Makras P. Osteoporos Int. PMID 26694593

113. 2016

     Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease

     Polyzos SA, Anastasilakis AD, Kountouras J, …, Makras P, et al. J Bone Miner Metab. PMID 26056025

114. 2015

     Novel therapies for osteoporosisΠρώτος συγγραφέας

     Makras P, Delaroudis S, Anastasilakis AD. Metabolism. PMID 26277199

115. 2015

     Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markersΤελευταίος συγγραφέας

     Anastasilakis AD, Polyzos SA, Efstathiadou ZA, …, Makras P, et al. Metabolism. PMID 26198440

116. 2015

     Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

     Hadji P, Papaioannou N, Gielen E, …, Makras P, et al. Osteoporos Int. PMID 26018090

117. 2015

     Denosumab versus zoledronic acid in patients previously treated with zoledronic acidΤελευταίος συγγραφέας

     Anastasilakis AD, Polyzos SA, Gkiomisi A, …, Makras P, et al. Osteoporos Int. PMID 25990355

118. 2015

     Cost-effective osteoporosis treatment thresholds in GreeceΠρώτος συγγραφέας

     Makras P, Athanasakis K, Boubouchairopoulou N, et al. Osteoporos Int. PMID 25740208

119. 2015

     Langerhans cell histiocytosis and pituitary functionΠρώτος συγγραφέας

     Makras P, Kaltsas G. Endocrine. PMID 25552340

120. 2015

     Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment

     Anastasilakis AD, Polyzos SA, Makras P, et al. Expert Opin Ther Targets. PMID 25395071

121. 2015

     Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosisΠρώτος συγγραφέας

     Makras P, Salagianni M, Revelos K, et al. J Clin Endocrinol Metab. PMID 25375981

122. 2015

     Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis

     Polyzos SA, Makras P, Efstathiadou Z, et al. Expert Opin Investig Drugs. PMID 25316089

123. 2014

     Estimating the Cost-Effective Intervention Thresholds for Osteoporotic Fractures Based on Frax® in the Greek Setting

     Athanasakis K, Makras P, Boubouchairopoulou N, et al. Value Health. PMID 27200839

124. 2014

     Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months

     Anastasilakis AD, Polyzos SA, Makras P, et al. Osteoporos Int. PMID 24599275

125. 2014

     Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment

     Anastasilakis AD, Polyzos SA, Makras P, et al. Horm Metab Res. PMID 23918682

126. 2013

     Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature

     Anastasilakis AD, Ruggeri RM, Polyzos SA, …, Makras P, et al. Metabolism. PMID 23806737

127. 2013

     Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trialΤελευταίος συγγραφέας

     Anastasilakis AD, Polyzos SA, Gkiomisi A, …, Makras P, et al. J Clin Endocrinol Metab. PMID 23788684

128. 2013

     Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net

     Girschikofsky M, Arico M, Castillo D, …, Makras P, et al. Orphanet J Rare Dis. PMID 23672541

129. 2013

     Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosisΠρώτος συγγραφέας

     Makras P, Polyzos SA, Papatheodorou A, et al. Clin Endocrinol (Oxf). PMID 23452098

130. 2013

     Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment

     Anastasilakis AD, Polyzos SA, Makras P, et al. Osteoporos Int. PMID 23124716

131. 2013

     Cladribine therapy in adults with advanced Langerhans cell histiocytosis

     Schini M, Makras P, Kanakis G, et al. Leuk Lymphoma. PMID 23101752

132. 2013

     Incidence of hip fractures in Greece during a 30-year period: 1977-2007Τελευταίος συγγραφέας

     Lyritis GP, Rizou S, Galanos A, …, Makras P. Osteoporos Int. PMID 23064370

133. 2012

     Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature

     Anastasilakis AD, Polyzos SA, Makras P, et al. Hormones (Athens). PMID 23422764

134. 2012

     Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumabΤελευταίος συγγραφέας

     Anastasilakis AD, Toulis KA, Polyzos SA, …, Makras P, et al. Ther Clin Risk Manag. PMID 22767993

135. 2012

     Performance of the mini nutritional assessment score in the detection of vitamin D status in an elderly Greek population

     Tsagari A, Toulis KA, Makras P, et al. Horm Metab Res. PMID 22692927

136. 2012

     The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone massΤελευταίος συγγραφέας

     Anastasilakis AD, Polyzos SA, Delaroudis S, …, Makras P, et al. Clin Endocrinol (Oxf). PMID 22676573

137. 2012

     2011 guidelines for the diagnosis and treatment of osteoporosis in GreeceΠρώτος συγγραφέας

     Makras P, Vaiopoulos G, Lyritis GP, et al. J Musculoskelet Neuronal Interact. PMID 22373950

138. 2012

     Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass

     Anastasilakis AD, Polyzos SA, Makras P, et al. Bone. PMID 22366634

139. 2012

     Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosisΠρώτος συγγραφέας

     Makras P, Polyzos SA, Anastasilakis AD, et al. J Clin Endocrinol Metab. PMID 22278426

140. 2012

     Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?Πρώτος συγγραφέας

     Makras P, Polyzos SA, Anastasilakis AD, et al. Mol Ther. PMID 22215051

141. 2012

     Reduced bone mineral density in adult patients with Langerhans cell histiocytosisΠρώτος συγγραφέας

     Makras P, Terpos E, Kanakis G, et al. Pediatr Blood Cancer. PMID 21548013

142. 2012

     Distinctive growth pattern in a patient with a delayed diagnosis of Langerhans' cell histiocytosisΤελευταίος συγγραφέας

     Anastasilakis AD, Kaltsas GA, Delimpasis G, …, Makras P, et al. Pituitary. PMID 21279449

143. 2011

     Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosisΤελευταίος συγγραφέας

     Toulis KA, Anastasilakis AD, Polyzos SA, …, Makras P. Hormones (Athens). PMID 22001129

144. 2011

     Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment

     Polyzos SA, Anastasilakis AD, Makras P, et al. Exp Clin Endocrinol Diabetes. PMID 21811962

145. 2011

     Adult case of Langerhans cell histiocytosis with single site vertebral involvementΤελευταίος συγγραφέας

     Paxinos O, Delimpasis G, Makras P. J Musculoskelet Neuronal Interact. PMID 21625059

146. 2011

     Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesisΤελευταίος συγγραφέας

     Anastasilakis AD, Polyzos SA, Anastasilakis CD, …, Makras P, et al. Med Hypotheses. PMID 21482033

147. 2011

     Skeletal implications of isolated bone marrow mastocytosisΠρώτος συγγραφέας

     Makras P. Haematologica. PMID 21454874

148. 2011

     No effect of rosuvastatin in the zoledronate-induced acute-phase responseΠρώτος συγγραφέας

     Makras P, Anastasilakis AD, Polyzos SA, et al. Calcif Tissue Int. PMID 21305270

149. 2011

     A case report of subacute thyroiditis during pregnancy: difficulties in differential diagnosis and changes in cytokine levels

     Anastasilakis AD, Karanicola V, Kourtis A, …, Makras P, et al. Gynecol Endocrinol. PMID 20528573

150. 2010

     Extensive and concurrent infiltration of an ectopic intrathoracic thyroid and thyroid gland by papillary thyroid cancer

     Sakorafas GH, Lappas C, Mastoraki A, …, Makras P, et al. Am Surg. PMID 21396268

151. 2010

     A 41-year-old man with a vertebral fracture and bone marrow mastocytosisΠρώτος συγγραφέας

     Makras P, Kokkoris P. J Musculoskelet Neuronal Interact. PMID 21116068

152. 2010

     Skeletal diseases in Cushing's syndrome: osteoporosis versus arthropathyΤελευταίος συγγραφέας

     Kaltsas G, Makras P. Neuroendocrinology. PMID 20829620

153. 2010

     Erythrocyte fatty acid composition and insulin sensitivity in daughters of Type 2 diabetic patients and women with no family history of diabetes

     Ntali G, Koutsari C, Karakike K, …, Makras P, et al. J Endocrinol Invest. PMID 20009492

154. 2009

     Medical treatment of hypercalcaemiaΠρώτος συγγραφέας

     Makras P, Papapoulos SE. Hormones (Athens). PMID 19570736

155. 2009

     Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosisΠρώτος συγγραφέας

     Makras P, Hamdy NA, Zwinderman AH, et al. Bone. PMID 19442613

156. 2009

     High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas

     Piaditis GP, Kaltsas GA, Androulakis II, …, Makras P, et al. Clin Endocrinol (Oxf). PMID 19226269

157. 2008

     Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosisΤελευταίος συγγραφέας

     Papapoulos S, Makras P. Nat Clin Pract Endocrinol Metab. PMID 18714329

158. 2008

     Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX geneΠρώτος συγγραφέας

     Makras P, Hamdy NA, Kant SG, et al. J Clin Endocrinol Metab. PMID 18252791

159. 2008

     Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities

     Alexandraki KI, Makras P, Protogerou AD, et al. QJM. PMID 18160417

160. 2007

     Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: a therapeutic challenge

     Papadogias D, Makras P, Kossivakis K, et al. Eur J Gastroenterol Hepatol. PMID 17998844

161. 2007

     Systemic and endocrine manifestations of Langerhans' cell histiocytosis: current concepts in diagnosis and managementΠρώτος συγγραφέας

     Makras P, Piaditis G, Kaltsas GA. Expert Rev Endocrinol Metab. PMID 30290476

162. 2007

     Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly

     Kaltsas GA, Androulakis II, Tziveriotis K, …, Makras P, et al. Clin Endocrinol (Oxf). PMID 17651451

163. 2007

     Endocrine manifestations in Langerhans cell histiocytosisΠρώτος συγγραφέας

     Makras P, Alexandraki KI, Chrousos GP, et al. Trends Endocrinol Metab. PMID 17600725

164. 2006

     The diagnosis and differential diagnosis of endogenous Cushing's syndromeΠρώτος συγγραφέας

     Makras P, Toloumis G, Papadogias D, et al. Hormones (Athens). PMID 17178699

165. 2006

     Evolving radiological features of hypothalamo-pituitary lesions in adult patients with Langerhans cell histiocytosis (LCH)Πρώτος συγγραφέας

     Makras P, Samara C, Antoniou M, et al. Neuroradiology. PMID 16292545

166. 2005

     Spontaneous gonadotrophin deficiency recovery in an adult patient with Langerhans cell histiocytosis (LCH)Πρώτος συγγραφέας

     Makras P, Papadogias D, Kontogeorgos G, et al. Pituitary. PMID 16379033

167. 2005

     Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues

     Kaltsas GA, Papadogias D, Makras P, et al. Endocr Relat Cancer. PMID 16322317

168. 2005

     Effect of 4 weeks of basic military training on peripheral blood leucocytes and urinary excretion of catecholamines and cortisolΠρώτος συγγραφέας

     Makras P, Koukoulis GN, Bourikas G, et al. J Sports Sci. PMID 16195034

169. 2005

     Treatment with oral biphosphonates can increase the sensitivity of sestamibi radionuclide imaging in patients with primary hyperparathyroidismΠρώτος συγγραφέας

     Makras P, Kaltsas GA, Athanasoulis T, et al. Int J Clin Pharmacol Res. PMID 15864874

170. 2004

     Growth without growth hormone (GH): a case reportΠρώτος συγγραφέας

     Makras P, Papadogias D, Kaltsas G, et al. Hormones (Athens). PMID 16982601

171. 2004

     Langerhans' cell histiocytosis in an adult patient manifested as recurrent skull lesions and Diabetes InsipidusΠρώτος συγγραφέας

     Makras P, Papadogias D, Samara C, et al. Hormones (Athens). PMID 16982579

172. 2003

     GH deficiency in adults

     Papadogias DS, Makras P, Kaltsas GA, et al. Hormones (Athens). PMID 17003026

173. 2001

     Outbreak of meningococcal disease after an influenza B epidemic at a Hellenic Air Force recruit training centerΠρώτος συγγραφέας

     Makras P, Alexiou-Daniel S, Antoniadis A, et al. Clin Infect Dis. PMID 11512107

Καμία δημοσίευση δεν ταιριάζει με την αναζήτηση.